Nov 29 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Applied Therapeutics, Brown-Forman and Ulta Beauty on Friday.
HIGHLIGHTS
* Applied Therapeutics Inc : RBC cuts to sector perform from outperform
* Brown-Forman : Barclays cuts target price to $49 from $53
* Descartes Systems Group Inc : RBC raises target price to $133 from $115
* The J.M. Smucker Company : Barclays raises target price to $126 from $121
* Ulta Beauty Inc : Citigroup raises target price to $390 from $345
Following is a summary of research actions on U.S. companies reported by Reuters on Thursday. Stock entries are in alphabetical order.
* Applied Therapeutics Inc : RBC cuts to sector perform from outperform
* Applied Therapeutics Inc : RBC cuts target price to $4 from $12
* Brown-Forman : Barclays cuts target price to $49 from $53
* CF Industries Holdings Inc : Berenberg raises target price to $74 from $69
* Descartes Systems Group Inc : RBC raises target price to $133 from $115
* Domo Inc : TD Cowen raises target price to $10 from $9
* Pfizer : Berenberg raises target price to $29 from $27
* Smurfit Westrock Plc : JP Morgan raises target price to $69 from $65
* Splash Beverage Group Inc : H.C. Wainwright cuts target price to $0.5 from $1
* The J.M. Smucker Company : Barclays raises target price to $126 from $121
* TXNM Energy : Barclays raises target price to $52 from $46
* Ulta Beauty Inc : Citigroup raises target price to $390 from $345
(Compiled by Bengaluru Newsroom)
((Diaries@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.